Does Blue Cross Blue Shield of Illinois Cover Jardiance?

Almost every Blue Cross Blue Shield of Illinois (BCBSIL) commercial, HMO, PPO, and Medicare Advantage plan places Jardiance (empagliflozin) somewhere on its formulary, because empagliflozin is a guideline-recommended treatment for type 2 diabetes with cardiovascular or kidney disease and because Boehringer Ingelheim's Jardiance holds multiple FDA approvals. What is not knowable from a general reference page is which tier your specific plan uses, whether prior authorization or step therapy applies to you, and what your copay will actually be. Those details are set by your employer group, your specific BCBSIL product, and the plan year, and they change. The only reliable answer for your situation comes from your plan's live formulary lookup or a call to member services with your member ID in hand.

This page separates what is stable and verifiable (FDA approval status, national guideline recommendations, how appeals generally work) from what is plan-specific and time-sensitive (tier placement, exact copay amounts, prior authorization turnaround times, manufacturer savings card terms). Treat the second category as directional, not as your actual benefit.

What Jardiance is and what it is FDA-approved to treat

Jardiance is the brand name for empagliflozin, an SGLT2 inhibitor made by Boehringer Ingelheim. It is FDA-approved for improving glycemic control in adults with type 2 diabetes, and it also carries approval for heart failure, with the specific ejection-fraction population and any chronic kidney disease indication defined by the current FDA label. Because empagliflozin's approved indications have expanded and been refined over several label updates, do not rely on this article for the exact current wording. Check the FDA's own current prescribing information for empagliflozin (Jardiance) before making a clinical decision.

The direct answer, with its boundary

Blue Cross Blue Shield of Illinois plans generally include Jardiance on their drug formularies because SGLT2 inhibitors are recommended by national diabetes guidelines for patients with type 2 diabetes and cardiovascular, kidney, or heart failure comorbidity, and because payers have strong clinical reasons not to exclude the class. This general inclusion is well supported. What is not established without checking your own plan is the specific tier, dollar copay, prior authorization criteria, and whether step therapy through metformin applies to you, since BCBSIL sells many distinct products (employer group, individual marketplace, Medicare Advantage) that do not share one formulary.

Why guidelines push insurers toward covering this drug class

The American Diabetes Association's Standards of Care recommends SGLT2 inhibitors such as empagliflozin as second-line therapy, independent of A1C, for people with type 2 diabetes who also have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. That guideline stance is one reason most major commercial insurers, including BCBSIL, keep the drug class accessible rather than excluding it. A guideline recommendation is not the same thing as a guarantee of a specific tier or copay on your plan; it explains why the drug is usually covered at all, not what you will pay.

Clinical trial evidence underlying that guideline position includes cardiovascular outcomes trials of empagliflozin in people with type 2 diabetes and established cardiovascular disease, a dedicated heart failure trial across reduced ejection fraction, and a chronic kidney disease outcomes trial. The general direction of these trials (reduced cardiovascular death or heart failure hospitalization, and slowed kidney disease progression, in the specific populations studied) is well established in the medical literature. The exact hazard ratios, confidence intervals, and p-values are easy to misquote from memory, so if a clinician or an appeal letter needs to cite precise trial numbers, those numbers should be pulled directly from the peer-reviewed publication or the FDA label rather than repeated from a secondary source, including this one.

Prior authorization and step therapy: what is standard practice, not what your plan requires

Prior authorization for SGLT2 inhibitors, including Jardiance, is common across commercial insurers, and step therapy requiring a documented trial of or intolerance to metformin first is also common. This is standard industry practice, not something unique to BCBSIL. What is not something a general article can tell you is the exact clinical documentation your specific BCBSIL plan requires, or how quickly it processes a request. Prior authorization turnaround times vary by plan, by whether the request is marked urgent, and by the specific BCBSIL product; do not plan around a specific number of hours or days without confirming it with your plan.

If your physician documents established cardiovascular disease, heart failure, or chronic kidney disease alongside type 2 diabetes, that documentation generally strengthens a prior authorization or appeal, because it aligns with the population in which SGLT2 inhibitors have shown benefit beyond blood sugar control. This is a plausible and clinically reasonable connection, but whether it changes the outcome of your specific request depends on your plan's internal criteria, which BCBSIL does not publish in a way a general article can summarize accurately.

What Jardiance is likely to cost, and why a specific number is not trustworthy here

Brand-name SGLT2 inhibitors without insurance are expensive, generally in the hundreds of dollars for a 30-day supply, and coverage substantially lowers that cost through tier-based copay or coinsurance. Beyond that general statement, this article cannot responsibly give you a dollar figure for your BCBSIL copay. Retail cash prices change, formulary tiers differ by product and plan year, and coinsurance percentages depend on whether you have met your deductible. Any specific dollar range you see online, including in outdated versions of pages like this one, should be treated as illustrative at best and verified against your plan documents.

Boehringer Ingelheim has historically offered a manufacturer copay savings program for commercially insured patients that is not usable with Medicare, Medicaid, or other government insurance. Savings card terms, maximum annual benefit, and eligibility rules change periodically, so confirm current terms directly on the manufacturer's own Jardiance website or by calling the number on the card, rather than relying on a fixed dollar figure from a secondary source.

For Medicare Advantage members, Jardiance is covered as a Part D drug, and cost-sharing in the initial coverage phase is typically higher than commercial coinsurance. The Inflation Reduction Act capped total annual out-of-pocket Part D spending, with the cap taking effect in 2025; the current cap amount and any subsequent adjustment should be confirmed on the CMS page rather than assumed to be fixed indefinitely: CMS: The Inflation Reduction Act and Medicare. The Medicare Extra Help (Low-Income Subsidy) program can reduce Part D cost-sharing for patients who qualify by income; the specific copay amounts under Extra Help are published and updated by CMS and should be checked for the current year rather than repeated as a fixed figure.

Separately, research on reducing patient cost-sharing in other chronic disease contexts, including a randomized trial of reduced cost-sharing and medication management services in COPD, has found that lowering out-of-pocket burden and adding structured medication support can improve outcomes tied to adherence (Reduced Cost Sharing and Medication Management Services for COPD: A Randomized Clinical Trial). That trial was conducted in COPD patients, not people with diabetes on Jardiance, so it supports the general principle that cost-sharing reductions can matter for adherence, not a specific claim about Jardiance or BCBSIL.

If BCBSIL denies coverage

A denial is not final. The standard path is a formulary exception request from your prescriber, including a letter of medical necessity, relevant labs (A1C, eGFR, urine albumin-to-creatinine ratio if applicable), and documentation of any cardiovascular, heart failure, or kidney disease diagnosis that supports guideline-based use of an SGLT2 inhibitor. BCBSIL, like other insurers, offers internal appeal levels, and Illinois residents whose internal appeals are exhausted can request an external review through the Illinois Department of Insurance, which uses independent physician reviewers whose decisions bind the insurer. The general appeals structure (internal appeal, then state external review) is standard for Illinois-regulated plans; the specific number of internal appeal levels and processing timelines for your product should be confirmed in your plan's denial letter, which is required to state them.

Jardiance versus other SGLT2 inhibitors on the same formulary

BCBSIL formularies commonly include more than one SGLT2 inhibitor, and dapagliflozin (Farxiga) sometimes sits at a different tier than empagliflozin depending on rebate arrangements the plan has negotiated. If your plan makes one drug cheaper than the other, that is a real cost consideration, but it is not automatically a clinical equivalence decision. Empagliflozin and dapagliflozin have both been studied in large cardiovascular and kidney outcomes trials, and their approved indications and trial populations are not identical. A switch driven purely by formulary cost should still involve your prescriber confirming that the alternative drug's evidence base fits your specific cardiovascular, heart failure, or kidney disease profile, not just your glucose control.

What is established, what is plausible, and what is not established

Established: empagliflozin is FDA-approved for type 2 diabetes and for heart failure; SGLT2 inhibitors are guideline-recommended second-line therapy for type 2 diabetes with cardiovascular, heart failure, or kidney disease; BCBSIL, like nearly all major commercial and Medicare Advantage insurers, generally includes SGLT2 inhibitors somewhere on its formulary; prior authorization and step therapy are common industry practice for this drug class; Illinois has a state external review process for denied claims; the IRA's Part D out-of-pocket cap took effect in 2025.

Plausible but unproven at the individual-plan level: that documenting cardiovascular or kidney disease in a prior authorization request meaningfully raises approval odds on any specific BCBSIL product; that switching to a lower-tier SGLT2 inhibitor produces equivalent clinical benefit for a given patient.

Not established by this article: the exact tier, copay, coinsurance percentage, prior authorization turnaround time, or manufacturer savings card terms for your specific BCBSIL plan. These require direct verification and are not the kind of fact a general reference page can state accurately for every reader.

Verification checklist: stable facts versus facts you must confirm yourself

Use this to separate what you can trust from a general source versus what only your plan can tell you.

Stable, generally reliable without a live lookup (verify against primary source, not memory):

• Whether empagliflozin/Jardiance carries FDA approval for a given indication (type 2 diabetes, heart failure), check the FDA label page directly, since indications have been updated over time.
• Whether SGLT2 inhibitors are guideline-recommended for type 2 diabetes with cardiovascular, heart failure, or kidney disease, check current ADA Standards of Care.
• Whether Illinois offers external review after exhausted internal appeals, check the Illinois Department of Insurance.
• Whether the Medicare Part D annual out-of-pocket cap took effect in 2025, check CMS's IRA page for the current cap amount.

Date-sensitive and plan-specific, requires direct verification before you rely on it:

• Which formulary tier your specific BCBSIL plan assigns to Jardiance (varies by product and plan year).
• Whether prior authorization or step therapy applies to your plan, and what documentation it requires.
• Your actual copay or coinsurance amount at your pharmacy, after deductible status is applied.
• Current manufacturer savings card eligibility, dollar cap, and whether it applies to your insurance type.
• Current Medicare Extra Help copay amounts for the plan year you are in.
• Cash price of Jardiance without insurance, which changes over time.

How to verify the second list: log into the BCBSIL member portal and use the pharmacy formulary lookup tool with your specific plan selected, call BCBSIL member services with your member ID, or ask your prescriber's office to run a real-time benefit check through their electronic health record system before the prescription is sent to the pharmacy.